Document is current
Any future updates will be listed below
-
Authors
Uchida, Megumi
Furukawa, Toshiaki A
Yamaguchi, Takuhiro
Imai, Fuminobu
Momino, Kanae
Katsuki, Fujika
Sakurai, Naomi
Miyaji, Tempei
Horikoshi, Masaru
Iwata, Hiroji
Zenda, Sadamoto
Iwatani, Tsuguo
Ogawa, Asao
Inoue, Akira
Abe, Masakazu
Toyama, Tatsuya
Uchitomi, Yosuke
Matsuoka, Hiromichi
Noma, Hisashi
Akechi, Tatsuo https://orcid.org/0000-0003-1100-7518
-
Funding
Funding for this research was provided by:
the Japan Agency for Medical Research and Development (20ck0106600h0001)
the Japanese Ministry of Education, Culture, Science and Technology (19H03586)
- License Information
-
More Information
Article History
Received: 15 March 2022
Accepted: 11 April 2023
First Online: 22 May 2023
Declarations
:
: The protocol was approved by the Institutional Review Board of Nagoya City University on July 15, 2020 (ID: 46-20-0005). All participants will provide electronic informed consent (e-consent) via the e-PRO system prior to participation.
: Not applicable.
: TA has received lecture fees from AstraZeneca, Daiichi-Sankyo, Dainippon-Sumitomo, Hisamitsu, Janssen, Kyowa, Lilly, MSD, Meiji-seika Pharma, Mochida, Nipro, Nihon-Zoki, Otsuka, Pfizer, Takeda, and Tsumura. TA also received royalties from Igaku-shoin and research funds from Daiichi-Sankyo, Eisai, FUJIFILM RI Pharma, MSD, Otsuka, and Shionogi. TA is the inventor of pending patents (2019-017498 & 2020-135195). TAF reports grants and personal fees from Mitsubishi-Tanabe and personal fees outside the submitted work from MSD and Shionogi. In addition, TAF has a pending patent (2018-177688) concerning the smartphone CBT app and intellectual properties for the Kokoro-app licensed to Mitsubishi-Tanabe. FK received speaker fees from Otsuka Pharmaceutical Co., Ltd., as well as grants from the Japanese Ministry of Education, Science, and Technology. TI received honoraria from Chugai, AstraZeneca, Lilly, Pfizer, Daiichi-Sankyo, Kyowa Hakko Kirin, Taiho, and Eisai. TI was paid for consulting or advisory roles from Chugai, AstraZeneca, Lilly, Pfizer, Daiichi-Sankyo, Kyowa, and Hakko Kirin. TI has also received research funds from Chugai, AstraZeneca, Lilly, Pfizer, Daiichi-Sankyo, Kyowa Hakko Kirin, MSD, Sanofi, Novartis, Bayer, Nihon Kayaku, and Boehringer Ingelheim. YU received grants from the Japanese Ministry of Health, Labor and Welfare, the Japan Health Research Promotion Bureau, and the National Cancer Center Japan.
